II. Precautions: Pharmacogenetics
- See Pharmacogenetics
- Poor metabolizers (2-15%, 20% in asians)
- Clopidogrel with reduced conversion to active form (higher risk for stent closure)
- Amitriptyline and Nortriptyline risk of toxicity (reduce starting dose by 50%)
- Citalopram, Escitalopram, Sertraline risk of toxicity (reduce starting dose by 50%)
- Omeprazole blood concentrations are 5x higher (increased efficacy)
- Ultra-Metabolizers (18% of Swedes and 18% of Ethiopians)
- Citalopram, Escitalopram, Sertraline with reduced effect (consider alternative agents)
- Omeprazole blood concentrations are 40% lower
- Reference
III. Interactions: Metabolized by CYP2C19 (Substrates)
- Neuropsychiatric drugs
- Cardiopulmonary Drugs
- Antibiotics
- Miscellaneous
- Lansoprazole
- Pentamidine
- Felbamate
- Omeprazole (Prilosec)
IV. Interactions: Inhibitor of CYP2C19
- Neuropsychiatric drugs
- Antibiotics
- Miscellaneous
V. Interactions: Inducer of CYP2C19
- Neuropsychiatric Drugs
- Antibiotics